Amgen scraps or halts a slate of 5 cancer studies in a series of setbacks raising fresh doubts about its BiTE plans

Amgen rolled out their Q4 numbers Tuesday afternoon, while flagging that a long lineup of its cancer therapy studies has been halted as they review safety questions on one top drug and evidently scrap several others in a pipeline reorganization. At the top of the list is the closely-watched BCMA…